A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer

Annals of Oncology

Volumn 12, Issue 9, 2001, Pages 1255-1257

  Skovsgaard, T ^a   Davidson, N G P ^b   Piccart, M J ^c   Richel, D J ^d   Bonneterre, J ^e   Cirkel, D T ^f   Barton, C M ^f   Knight, S ^f  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^c JULES BORDET INSTITUTE   (Belgium)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

^e CENTRE OSCAR LAMBRET   (France)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 fluorouracil; Anthracycline refractory; Breast cancer; Eniluracil; Taxane refractory

Indexed keywords

5 ETHYNYLURACIL; ANTHRACYCLINE DERIVATIVE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CATABOLISM; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INACTIVATION; HAND FOOT AND MOUTH DISEASE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

EID: 0034777468     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012249630074     Document Type: Article

References (12)

1. Continuous 5-fluorouracil in refractory carcinoma of the breast
2. Low-dose continuous infusion 5-fluorouracil: Evaluation in advanced breast carcinoma
3. 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo
4. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
5. Low dose 5-fluorouracil with eniluracil (776C85) as first-line chemotherapy against advanced breast cancer: A phase II study
6. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
7. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin and cyclophosphamide for advanced breast cancer
8. Review of recent trials of chemotherapy for advanced breast cancer: The taxanes
9. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer
10. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
11. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
12. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase